journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Gastroenterology

journal
https://www.readbyqxmd.com/read/28804517/update-on-the-role-of-nanoliposomal-irinotecan-in-the-treatment-of-metastatic-pancreatic-cancer
#1
REVIEW
Fnu Asad Ur Rahman, Saeed Ali, Muhammad Wasif Saif
Median survival for patients with metastatic pancreatic cancer (MPC) treated with combination chemotherapeutic agents such as gemcitabine-based regimens and FOLFIRINOX is currently less than 12 months. This highlights the need for more efficacious first-line, as well as second-line therapies. Nanoliposomal irinotecan, in combination with 5-fluorouracil (5-FU)/folinic acid has recently been assessed as second-line therapy after initial gemcitabine-based therapy. It is the first, second-line treatment approved by the US Food and Drug Administration to treat patients with MPC based on results of the NAnoliPOsomaL Irinotecan (NAPOLI-1) study, which showed that this regimen significantly prolonged progression-free survival (3...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28804516/the-role-of-sebelipase-alfa-in-the-treatment-of-lysosomal-acid-lipase-deficiency
#2
REVIEW
Angelika L Erwin
Lysosomal acid lipase deficiency (LALD) is a lysosomal storage disorder (LSD) characterized either by infantile onset with fulminant clinical course and very poor prognosis or childhood/adult-onset disease with an attenuated phenotype. The disorder is often misdiagnosed or remains undiagnosed in children and adults due to a rather unspecific clinical presentation with dyslipidemia and steatohepatitis. Until recently, no good treatment options were available for LALD. Despite supportive and symptomatic therapies, death occurred before 1 year of age in patients with infantile-onset disease and patients with childhood/adult-onset LALD suffered from significant complications, such as liver cirrhosis, requiring liver transplantation and early-onset cardiovascular disease...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28804515/mmx-%C3%A2-technology-and-its-applications-in-gastrointestinal-diseases
#3
REVIEW
Silvia Nardelli, Laura Francesca Pisani, Gian Eugenio Tontini, Maurizio Vecchi, Luca Pastorelli
The Multimatrix(®) (MMX(®)) preparation MMX(®) is a recently obtained drug formulation developed to facilitate release of high concentrations of active drugs into the colon, with a homogeneous distribution along all colonic segments, particularly the most distal ones; the distal colonic tracts, indeed, are the most difficult to reach in significant amounts when a drug is given orally. The MMX(®) formulation is characterized by a lipophilic matrix dispersed in a hydrophilic structure. Indeed, in the last few years, MMX(®) technology has been widely used in the development of various drugs for the treatment of inflammatory and infectious gastrointestinal diseases localized in the colon...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28804514/is-eus-guided-drainage-a-suitable-alternative-technique-in-case-of-proximal-biliary-obstruction
#4
Frédérick Moryoussef, Adrien Sportes, Sarah Leblanc, Jean Baptiste Bachet, Stanislas Chaussade, Frédéric Prat
BACKGROUND: Results of endoscopic ultrasound-guided biliary drainage (EUBD) are unknown in case of proximal stricture. The aim is to assess clinical outcomes of EUBD in patients with malignant hilar obstruction. METHODS: Patients undergoing EUBD with hilar strictures were prospectively included. Primary outcome was clinical success at 7 and 30 days (defined by 50% bilirubin decrease). Secondary outcomes were technical success, procedure-related complications, length of hospital stay, reintervention rate, survival and chemotherapy administration...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28804513/noncirrhotic-hepatocellular-carcinoma-etiology-and-occult-hepatitis-b-virus-infection-in-a-hepatitis-b-virus-endemic-area
#5
Chang Woo Shim, Joong-Won Park, So Hee Kim, Jin Sook Kim, Bo Hyun Kim, Sung Hoon Kim, Eun Kyung Hong
BACKGROUND: Although hepatocellular carcinoma (HCC) usually develops in cirrhotic livers, a minority of cases occur in noncirrhotic livers (NCLs). We investigated etiology, clinicopathological features, and occult hepatitis B virus (HBV) infection (OBI) in patients with NCL HCC in an HBV-endemic area. METHODS: A total of 710 patients who underwent resection or transplantation for HCC at the National Cancer Center (NCC), Korea, were enrolled. HCC and fibrosis stage were diagnosed pathologically...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567121/an-alternative-treatment-for-biliary-injuries-characterized-by-complete-transection-of-the-common-bile-duct-intraperitoneal-rendezvous
#6
Bulent Odemis, Erkin Oztas, Muhammet Yener Akpinar, Ensar Ozdemir, Serkan Torun, Orhan Coskun
No abstract text is available yet for this article.
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567120/the-potential-role-of-comprehensive-genomic-profiling-to-guide-targeted-therapy-for-patients-with-biliary-cancer
#7
REVIEW
Hwajeong Lee, Jeffrey S Ross
Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract cancer (BTC). Recent largescale molecular profiling studies have not only highlighted genomic differences characterizing tumors of the intrahepatic and extrahepatic bile ducts and gallbladder, but have also revealed differences in genomic profiles pertaining to associated risk factors. Novel genomic alterations such as FGFR2 fusions and IDH1/2 mutations in intrahepatic cholangiocarcinoma (ICC) and ERBB2 alterations in gallbladder cancer (GBCA) are emerging as targeted therapy options capable of advancing precision medicine for the care of these patients...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567119/direct-oral-anticoagulants-and-digestive-bleeding-therapeutic-management-and-preventive-measures
#8
REVIEW
David Deutsch, Christian Boustière, Emile Ferrari, Pierre Albaladejo, Pierre-Emmanuel Morange, Robert Benamouzig
The use of direct oral anticoagulants (DOACs) was an important step forward in the management of atrial fibrillation and venous thromboembolism (VTE). The DOACs, anti-IIa for dabigatran and anti-Xa for rivaroxaban, apixaban and edoxaban, all have a rapid onset of action and a short half life. There is no need for routine hemostasis testing for treatment monitoring of a DOAC. Compared with vitamin K antagonists (VKAs), DOACs may increase the risk of gastrointestinal bleeding (relative risk 1.25). Withholding the DOAC treatment, evaluating the time of the last intake and estimating the patient's renal function are the first steps in the management of gastrointestinal bleeding...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567118/endoscopic-ultrasound-guided-hepaticogastrostomy-versus-percutaneous-transhepatic-drainage-for-malignant-biliary-obstruction-after-failed-endoscopic-retrograde-cholangiopancreatography-a-retrospective-expertise-based-study-from-two-centers
#9
Adrien Sportes, Marine Camus, Michel Greget, Sarah Leblanc, Romain Coriat, Jürgen Hochberger, Stanislas Chaussade, Sophie Grabar, Frédéric Prat
BACKGROUND: Percutaneous transhepatic biliary drainage (PTBD) is widely performed as a salvage procedure in patients with unresectable malignant obstruction of the common bile duct (CBD) after failed endoscopic retrograde cholangiopancreatography (ERCP) or in case of surgically altered anatomy. Endoscopic ultrasound-guided hepaticogastrostomy (EU-HGS) is a more recently introduced alternative to relieve malignant obstructive jaundice. The aim of this prospective observational study was to compare the outcome, efficacy and adverse events of EU-HGS and PTBD...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567117/commercially-available-glutenases-a-potential-hazard-in-coeliac-disease
#10
Suneeta Krishnareddy, Kenneth Stier, Maya Recanati, Benjamin Lebwohl, Peter Hr Green
BACKGROUND: The only treatment for celiac disease (CD) is a gluten-free diet (GFD). However, there is interest among patients in a medical therapy to replace or help with a GFD. Therapies include gluten-degrading enzymes (glutenases). There are glutenases available marketed as dietary supplements that have not been demonstrated to digest the toxic epitopes of gluten. METHODS: We investigated the contents, claims, and disclaimers of glutenase products and assessed patient interest using Google AdWords to obtain Google search frequencies...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567116/efficacy-of-double-balloon-enteroscopy-for-small-bowel-polypectomy-clinical-and-economic-evaluation
#11
Gabriel Rahmi, Marie-Amélie Vinet, Guillaume Perrod, Jean-Christophe Saurin, Elia Samaha, Thierry Ponchon, Jean-Marc Canard, Joël Edery, Hassani Maoulida, Gilles Chatellier, Isabelle Durand-Zaleski, Christophe Cellier
BACKGROUND: We evaluated first the feasibility of endoscopic small-bowel polypectomy and second, the economic aspects, by comparing the cost of endoscopic and surgical polyp resection. METHODS: A prospective, observational, multicenter study included 494 patients with positive capsule endoscopy (CE) before double-balloon enteroscopy (DBE). We selected only CE with at least one polyp. The retrospective economic evaluation compared patients treated by DBE or surgery for small-bowel polypectomy...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567115/factors-associated-with-the-achievement-of-mucosal-healing-in-crohn-s-disease-the-benefit-of-endoscopic-monitoring-in-treating-to-target
#12
Ren Mao, Yun Qiu, Bai-Li Chen, Sheng-Hong Zhang, Rui Feng, Yao He, Zhi-Rong Zeng, Shomron Ben-Horin, Min-Hu Chen
BACKGROUND: Mucosal healing (MH), the proposed treat to target in Crohn's disease (CD), is associated with improved disease outcomes. There are still scant data on factors associated with achieving MH in clinical practice. We evaluated the probability of achieving MH and identified factors predictive of subsequent MH in patients with CD. METHODS: This was a retrospective, observational cohort study. A total of 272 patients with CD with serial endoscopy assessment and subsequent therapeutic management were reviewed...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28567114/a-randomized-double-blind-study-to-evaluate-the-acid-inhibitory-effect-of-vonoprazan-20-mg-and-40-mg-in-patients-with-proton-pump-inhibitor-resistant-erosive-esophagitis
#13
Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Kentaro Kudou, Akira Nishimura, Naoki Hiramatsu, Eiji Umegaki, Kiyoshi Ashida
BACKGROUND: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant EE. METHODS: This randomized, double-blind, multicenter study of vonoprazan evaluated gastric and esophageal pH over a 24-hour period as the primary endpoint and EE healing rate as the secondary endpoint...
June 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28507601/end-of-treatment-rna-positive-sustained-viral-response-in-an-individual-with-acute-hepatitis-c-virus-infection-treated-with-direct-acting-antivirals
#14
Eyal Shteyer, Harel Dahari, Ina Gafanovich, Ilana Dery, Dana Wolf, Scott J Cotler, Yoav Lurie
No abstract text is available yet for this article.
May 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28507600/insights-into-the-role-of-the-intestinal-microbiota-in-colon-cancer
#15
REVIEW
Sofia Oke, Alberto Martin
The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbiota is multifaceted in its ability to induce colorectal cancer, this review will focus on the capability of the microbiota to induce colorectal cancer through the modulation of immune function and the production of microbial-derived metabolites...
May 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28507599/comparison-of-relapse-free-survival-in-gastric-neuroendocrine-carcinoma-who-grade-3-and-gastric-carcinoma
#16
Beom Su Kim, Young Soo Park, Jeong Hwan Yook, Byung-Sik Kim
BACKGROUND: We compared relapse-free survival (RFS) in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma (GC). This is one of very few studies that compare the prognosis of poorly differentiated neuroendocrine carcinoma (WHO grade 3, G3 NEC) with that of GC. METHODS: Between 1996 and 2014, 63 patients were diagnosed with G3 NEC of the stomach and 56 with gastric neuroendocrine tumors (NETs) with GC at Asan Medical Center in Seoul, Korea. We also randomly selected 762 patients diagnosed with GC between 1999 and 2008...
May 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28507598/thalidomide-induces-clinical-remission-and-mucosal-healing-in-adults-with-active-crohn-s-disease-a-prospective-open-label-study
#17
Yao He, Ren Mao, Fang Chen, Ping-Ping Xu, Bai-Li Chen, Yun Wu, Yun Qiu, Sheng-Hong Zhang, Rui Feng, Zhi-Rong Zeng, Shomron Ben-Horin, Min-Hu Chen
BACKGROUND: Thalidomide is effective in inducing and maintaining clinical remission in children and adolescents with refractory Crohn's disease (CD). However, little is known about the efficacy and safety of thalidomide for adult patients with CD. METHODS: We conducted a prospective open-label cohort study between January 2013 and April 2015. A total of 47 adult patients with active CD who were dependent/resistant or intolerant to corticosteroids and/or immunomodulators or biologics received 50-100 mg of thalidomide daily...
May 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28507597/low-adherence-to-national-guidelines-for-proton-pump-inhibitor-prescription-in-patients-receiving-combination-aspirin-and-anticoagulation
#18
Rajani Sharma, Abhik Roy, Christopher Ramos, Richard Rosenberg, Reuben Garcia-Carrasquillo, Benjamin Lebwohl
BACKGROUND: Aspirin, when used with concurrent anticoagulation, increases the risk of gastrointestinal bleeding (GIB). Therefore, multisociety guidelines recommend prophylactic proton-pump inhibitors (PPIs) for patients receiving aspirin and anticoagulation. We aimed to determine rates and predictors of adherence to these recommendations. METHODS: All adult inpatients discharged from the hospital on aspirin and anticoagulation from July 2009 to June 2014 were retrospectively evaluated for PPI prescription on discharge instructions...
May 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28491142/current-challenges-in-the-treatment-of-severe-clostridium-difficile-infection-early-treatment-potential-of-fecal-microbiota-transplantation
#19
REVIEW
Yvette H van Beurden, Max Nieuwdorp, Pablo J E J van de Berg, Chris J J Mulder, Abraham Goorhuis
Fecal microbiota transplantation (FMT) is a very effective treatment for recurrent Clostridium difficile infection (CDI). Less is known about the application of FMT as a curative treatment of severe or complicated CDI. In this review, we present and discuss evidence supporting the curative use of FMT in severe or complicated CDI. We performed a literature search in PubMed and Embase for studies on the curative use of FMT in severe or complicated CDI. In addition, we describe a patient with severe CDI not responding to initial antibiotic treatment, who was successfully treated with curative FMT...
April 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28491141/universal-molecular-screening-does-not-effectively-detect-lynch-syndrome-in-clinical-practice
#20
Beatrice Brennan, Christine T Hemmings, Ian Clark, Desmond Yip, Mitali Fadia, Douglas R Taupin
BACKGROUND: Lynch syndrome (LS) due to an inherited damaging mutation in mismatch repair (MMR) genes comprises 3% of all incident colorectal cancer (CRC). Molecular testing using immunohistochemistry (IHC) for MMR proteins is a recommended screening tool to identify LS in incident CRC. This study assessed outcomes of population-based routine molecular screening for diagnosis of LS in a regional center. METHODS: We conducted a prospective, consecutive case series study of universal IHC testing on cases of resected CRC from September 2004-December 2013...
April 2017: Therapeutic Advances in Gastroenterology
journal
journal
42067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"